Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial (NCT05411081)
A Phase II Randomized Trial of Cabozantinib (NSC #761968) With or Without Atezolizumab (NSC #783608) in Patients With Advanced Papillary Renal Cell Carcinoma (PAPMET2)
🩺 Plain-English Summary (8th-Grade Level)
This phase II trial compares the effect of atezolizumab in combination with usual treatment with cabozantinib to cabozantinib alone in patients with papillary renal cell carcinoma that has spread from where it first started (primary site) to other places in the body (metastatic). Papillary renal cell carcinoma (PRCC) is a type of kidney cancer that forms in the lining of the tiny tubes in the kidney that return filtered substances that the body needs back to the blood and remove extra fluid and waste as urine. Most papillary tumors look like long, thin finger-like growths under a microscope. It is also called papillary kidney cancer or PRCC. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the tumor and may interfere with the ability of tumor cells to grow and spread. Cabozantinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals tumor cells to multiply and may also prevent the growth of new blood vessels that tumors need to grow. By these actions it may help slow or stop the spread of tumor cells. Combination therapy with atezolizumab and cabozantinib may shrink the tumor and allow a longer survival time in patients with metastatic renal cell carcinoma.
Who can join: Review the eligibility criteria below.
Location: Banner MD Anderson Cancer Center — Gilbert, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (198 Sites)
Showing the first 25 of 198 sites.
- Banner MD Anderson Cancer Center — Gilbert, Arizona
- Cancer Center at Saint Joseph's — Phoenix, Arizona
- University of Arkansas for Medical Sciences — Little Rock, Arkansas
- Kaiser Permanente-Anaheim — Anaheim, California
- Kaiser Permanente-Baldwin Park — Baldwin Park, California
- Kaiser Permanente-Bellflower — Bellflower, California
- City of Hope Comprehensive Cancer Center — Duarte, California
- Epic Care-Dublin — Dublin, California
- Epic Care Partners in Cancer Care — Emeryville, California
- Kaiser Permanente-Fontana — Fontana, California
- Kaiser Permanente South Bay — Harbor City, California
- Kaiser Permanente-Irvine — Irvine, California
- Kaiser Permanente Los Angeles Medical Center — Los Angeles, California
- Kaiser Permanente West Los Angeles — Los Angeles, California
- Contra Costa Regional Medical Center — Martinez, California
- Kaiser Permanente-Ontario — Ontario, California
- Kaiser Permanente - Panorama City — Panorama City, California
- Kaiser Permanente-Riverside — Riverside, California
- University of California Davis Comprehensive Cancer Center — Sacramento, California
- Kaiser Permanente-San Diego Zion — San Diego, California
- Kaiser Permanente-San Marcos — San Marcos, California
- Epic Care Cyberknife Center — Walnut Creek, California
- Kaiser Permanente-Woodland Hills — Woodland Hills, California
- MedStar Georgetown University Hospital — Washington D.C., District of Columbia
- Saint Alphonsus Cancer Care Center-Boise — Boise, Idaho
📞 Contact the Study Coordinator
Phone: (877) 632-6789
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
Explore by condition: All Metastatic Papillary Renal Cell Carcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.